Table of Contents Author Guidelines Submit a Manuscript
Volume 11, Pages 742-748
Review Article

Methods to Predict and Lower the Risk of Prostate Cancer

Department of Urology, University of Texas Health Science Center, San Antonio, USA

Received 30 September 2010; Revised 21 February 2011; Accepted 1 March 2011

Academic Editor: Scott Eggener

Copyright © 2011 Barbara Ercole and Dipen J. Parekh.


Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5α-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.